{"id":2166,"date":"2017-06-13T17:41:21","date_gmt":"2017-06-13T12:11:21","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2166"},"modified":"2021-07-24T12:56:46","modified_gmt":"2021-07-24T07:26:46","slug":"notizia-43","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-43","title":{"rendered":"Invokana matches; Xultophy beats; Lilly and BI follow; Tresiba matches"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f4c594866d9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f4c594866d9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-43\/#J_Js_Invokana_matches_Jardiances_14_reduction_in_major_CV_events\" >J&amp;J&#8217;s Invokana matches Jardiance&#8217;s 14% reduction in major CV events<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-43\/#Novos_Xultophy_beats_basal-bolus_insulin_at_cutting_hypoglycemia_spurring_weight_loss\" >Novo&#8217;s Xultophy beats basal-bolus insulin at cutting hypoglycemia, spurring weight loss<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-43\/#Lilly_and_BI_following_their_SGLT2_rivals_plot_kidney_disease_study_for_Jardiance\" >Lilly and BI, following their SGLT2 rivals, plot kidney disease study for Jardiance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-43\/#Novos_Tresiba_matches_Sanofi_rival_Lantus_in_CV_safety_study\" >Novo&#8217;s Tresiba matches Sanofi rival Lantus in CV safety study<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"J_Js_Invokana_matches_Jardiances_14_reduction_in_major_CV_events\"><\/span>J&amp;J&#8217;s Invokana matches Jardiance&#8217;s 14% reduction in major CV events<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">There\u2019s officially another heart-helping SGLT2 on the block. But this one brings some varied benefits\u2014and amputation risks\u2014along with it. In a cardiovascular outcomes trial, Johnson &amp; Johnson&#8217;s Invokana matched up to Eli Lilly and Boehringer Ingelheim&#8217;s Jardiance at cutting a composite measure of CV risks, posting a 14% reduction. Those paying close attention may recognize that 14% is the same mark Jardiance hit back in 2015. But that\u2019s where the similarities between the two data sets end. Unlike Jardiance, which failed to make a significant difference in the risk of heart attack or stroke, Invokana pared down risks in both measures\u2014by 15% and 10%, respectively. On the flip side, though, while J&amp;J\u2019s entrant was able to slash the risk of cardiovascular death by 13% that number pales in comparison with Jardiance&#8217;s 38%\u2014a figure that now has a place on the Lilly\/BI med&#8217;s label.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Novos_Xultophy_beats_basal-bolus_insulin_at_cutting_hypoglycemia_spurring_weight_loss\"><\/span>Novo&#8217;s Xultophy beats basal-bolus insulin at cutting hypoglycemia, spurring weight loss<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Novo Nordisk is in a tough market race against Sanofi with combo product Xultophy, which hit the market after the French drugmaker\u2019s Soliqua. New basal-bolus topping data, though, could give the medicine a leg up. Xultophy\u2014which marries Novo&#8217;s newest basal insulin, Tresiba, with its top-selling GLP-1 med Victoza\u2014beat a &#8220;gold-standard&#8221; insulin therapy at helping Type 2 diabetes patients avoid hypoglycemia and weight gain, common side effects of insulin. And it did that while matching the older basal-bolus treatment&#8217;s ability to cut blood-sugar levels, a new study showed. Presented on Saturday at the American Diabetes Association\u2019s annual meeting, the trial pitted Xultophy against basal-bolus therapy with Sanofi&#8217;s standard basal insulin, Lantus, and Novo&#8217;s own mealtime insulin NovoLog. Xultophy took 66% of patients down below a 7% A1C target, similar to the 67% of patients who reached the mark with the basal-bolus duo.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Lilly_and_BI_following_their_SGLT2_rivals_plot_kidney_disease_study_for_Jardiance\"><\/span>Lilly and BI, following their SGLT2 rivals, plot kidney disease study for Jardiance<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Eli Lilly and Boehringer Ingelheim have reason to believe their SGLT2 inhibitor, Jardiance, may improve outcomes for chronic kidney disease patients\u2014so they\u2019re putting the medicine to the test. On Monday, in the middle of the American Diabetes Association\u2019s annual meeting, the pair announced plans to run a new outcomes trial specifically aimed at assessing Jardiance in kidney disease patients, both with and without diabetes. The companies based the decision on data from Empa-Reg Outcome, the cardiovascular outcomes trial that made headlines back in 2015 by showing Jardiance could cut the risk of major CV events by 14% and the risk of cardiovascular death by 38%. At last year\u2019s ADA meeting, the drugmakers unveiled a new analysis of the study showing that Jardiance had posted a 55% reduction in the initiation of renal replacement therapy, such as dialysis.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Novos_Tresiba_matches_Sanofi_rival_Lantus_in_CV_safety_study\"><\/span>Novo&#8217;s Tresiba matches Sanofi rival Lantus in CV safety study<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Going up against Sanofi blockbuster Lantus is no easy task, but that&#8217;s exactly what Novo Nordisk and its long-acting insulin Tresiba have to do. Thanks to new data, though, the Danish drugmaker can safely say its newcomer poses no increased heart risks\u2014and it has some advantages over its rival, too. On Monday at the American Diabetes Association annual meeting, Novo unveiled a 7,637-patient study showing that high-risk Type 2 diabetes patients taking Tresiba were no more likely to suffer a major cardiovascular event\u2014such as heart attack or stroke\u2014than those using Lantus were. It\u2019s good news for Novo, which kicked off the trial\u2014dubbed Devote\u2014after the FDA turned away Tresiba in early 2013. In sending Novo back to conduct a CV trial, the agency spurned the advice of an advisory panel, which had recommended a study post-approval instead of beforehand.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>J&amp;J&#8217;s Invokana matches Jardiance&#8217;s 14% reduction in major CV events There\u2019s officially another heart-helping SGLT2 on the block. But this one brings some varied benefits\u2014and amputation risks\u2014along with it. In a cardiovascular outcomes trial, Johnson &amp; Johnson&#8217;s Invokana matched up to Eli Lilly and Boehringer Ingelheim&#8217;s Jardiance at cutting a composite measure of CV risks, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1712,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[926,17539,921,809,17538,925,877,465,639,533,17540],"industry":[17225],"therapeutic_areas":[17240,17230],"class_list":["post-2166","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-bi","tag-hypoglycemia","tag-jj","tag-jardiance","tag-kidney-disease","tag-lily","tag-novo-nordisk","tag-pharma-companies","tag-pharma-news","tag-sanofi","tag-xultophy","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-genito-urinary-system-and-sex-hormones"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>J&amp;J&#039;s Invokana; Novo&#039;s Xultophy; Lilly &amp; BI&#039;s Jardiance; Novo&#039;s Tresiba<\/title>\n<meta name=\"description\" content=\"There\u2019s officially another heart-helping SGLT2 on the block. But this one brings some varied benefits\u2014and amputation risks...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-43\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"J&amp;J&#039;s Invokana; Novo&#039;s Xultophy; Lilly &amp; BI&#039;s Jardiance; Novo&#039;s Tresiba\" \/>\n<meta property=\"og:description\" content=\"There\u2019s officially another heart-helping SGLT2 on the block. But this one brings some varied benefits\u2014and amputation risks...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-43\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-06-13T12:11:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"343\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"J&J's Invokana; Novo's Xultophy; Lilly & BI's Jardiance; Novo's Tresiba","description":"There\u2019s officially another heart-helping SGLT2 on the block. But this one brings some varied benefits\u2014and amputation risks...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-43","og_locale":"en_US","og_type":"article","og_title":"J&J's Invokana; Novo's Xultophy; Lilly & BI's Jardiance; Novo's Tresiba","og_description":"There\u2019s officially another heart-helping SGLT2 on the block. But this one brings some varied benefits\u2014and amputation risks...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-43","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-06-13T12:11:21+00:00","article_modified_time":"2021-07-24T07:26:46+00:00","og_image":[{"width":960,"height":343,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-43","url":"https:\/\/www.delveinsight.com\/blog\/notizia-43","name":"J&J's Invokana; Novo's Xultophy; Lilly & BI's Jardiance; Novo's Tresiba","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-43#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-43#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","datePublished":"2017-06-13T12:11:21+00:00","dateModified":"2021-07-24T07:26:46+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"There\u2019s officially another heart-helping SGLT2 on the block. But this one brings some varied benefits\u2014and amputation risks...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-43"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-43#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","width":960,"height":343},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news-300x107.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BI<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hypoglycemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">J&amp;J<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Jardiance<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Kidney Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lily<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novo Nordisk<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Xultophy<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">BI<\/span>","<span class=\"advgb-post-tax-term\">Hypoglycemia<\/span>","<span class=\"advgb-post-tax-term\">J&amp;J<\/span>","<span class=\"advgb-post-tax-term\">Jardiance<\/span>","<span class=\"advgb-post-tax-term\">Kidney Disease<\/span>","<span class=\"advgb-post-tax-term\">Lily<\/span>","<span class=\"advgb-post-tax-term\">Novo Nordisk<\/span>","<span class=\"advgb-post-tax-term\">Pharma Companies<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>","<span class=\"advgb-post-tax-term\">Xultophy<\/span>"]}},"comment_count":"2","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jun 13, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jun 13, 2017 5:41 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2166"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2166\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1712"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2166"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2166"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}